CS263952B1 - Remedy with antiviral effect - Google Patents

Remedy with antiviral effect Download PDF

Info

Publication number: CS263952B1
Authority: CS; Czechoslovakia
Prior art keywords: formula; compounds; virus; cells; effect
Prior art date: 1985-04-25

Application number

CS853018A

Other languages

Czech (cs)

English (en)

Inventor

Antonin Rndr Drsc Holy

Ivan Ing Rosenberg

Original Assignee

Holy Antonin

Rosenberg Ivan

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-04-25

Filing date

1985-04-25

Publication date

1989-05-12

1985-04-25 Application filed by Holy Antonin, Rosenberg Ivan filed Critical Holy Antonin

1985-04-25 Priority to CS853018A priority Critical patent/CS263952B1/cs

1986-04-21 Priority to IL78553A priority patent/IL78553A/xx

1986-04-21 Priority to US06/854,087 priority patent/US4724233A/en

1986-04-22 Priority to AU56468/86A priority patent/AU586860B2/en

1986-04-22 Priority to DK184186A priority patent/DK167342B1/da

1986-04-24 Priority to EG241/86A priority patent/EG18436A/xx

1986-04-24 Priority to NZ215939A priority patent/NZ215939A/xx

1986-04-24 Priority to PH33699A priority patent/PH23112A/en

1986-04-24 Priority to PT82457A priority patent/PT82457B/pt

1986-04-24 Priority to CA000507510A priority patent/CA1272956A/en

1986-04-24 Priority to GR861089A priority patent/GR861089B/el

1986-04-25 Priority to DE8686105776T priority patent/DE3684363D1/de

1986-04-25 Priority to ZA863133A priority patent/ZA863133B/xx

1986-04-25 Priority to EP86105776A priority patent/EP0205826B1/de

1986-04-25 Priority to JP61097811A priority patent/JPH0692307B2/ja

1986-04-25 Priority to AT86105776T priority patent/ATE73663T1/de

1989-05-12 Publication of CS263952B1 publication Critical patent/CS263952B1/cs

1996-12-19 Priority to HK217296A priority patent/HK217296A/en

Links

230000000840 anti-viral effect Effects 0.000 title claims abstract description 11
241000700605 Viruses Species 0.000 claims abstract description 16
239000003814 drug Substances 0.000 claims abstract description 14
239000000126 substance Substances 0.000 claims description 21
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 6
239000004480 active ingredient Substances 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 4
229910052783 alkali metal Inorganic materials 0.000 claims description 3
-1 alkali metal salts Chemical class 0.000 claims description 3
150000001412 amines Chemical class 0.000 claims description 3
229910021529 ammonia Inorganic materials 0.000 claims description 3
150000007513 acids Chemical class 0.000 claims description 2
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
201000010099 disease Diseases 0.000 abstract description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
241000450599 DNA viruses Species 0.000 abstract description 4
GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract description 4
150000003839 salts Chemical class 0.000 abstract description 3
238000011282 treatment Methods 0.000 abstract description 2
150000001875 compounds Chemical class 0.000 description 31
210000004027 cell Anatomy 0.000 description 19
241000700588 Human alphaherpesvirus 1 Species 0.000 description 11
230000000694 effects Effects 0.000 description 10
241001529453 unidentified herpesvirus Species 0.000 description 9
241000700618 Vaccinia virus Species 0.000 description 8
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 6
239000000243 solution Substances 0.000 description 6
229930024421 Adenine Natural products 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
229960000643 adenine Drugs 0.000 description 5
ODZBBRURCPAEIQ-DJLDLDEBSA-N Brivudine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C=CBr)=C1 ODZBBRURCPAEIQ-DJLDLDEBSA-N 0.000 description 4
241000701074 Human alphaherpesvirus 2 Species 0.000 description 4
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 4
229960004150 aciclovir Drugs 0.000 description 4
238000010348 incorporation Methods 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
210000003292 kidney cell Anatomy 0.000 description 4
239000002243 precursor Substances 0.000 description 4
208000007514 Herpes zoster Diseases 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 2
206010008342 Cervix carcinoma Diseases 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
241000713862 Moloney murine sarcoma virus Species 0.000 description 2
206010035664 Pneumonia Diseases 0.000 description 2
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
230000001399 anti-metabolic effect Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
201000010881 cervical cancer Diseases 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
230000000120 cytopathologic effect Effects 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
230000007423 decrease Effects 0.000 description 2
MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 2
241001493065 dsRNA viruses Species 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
238000002372 labelling Methods 0.000 description 2
244000144972 livestock Species 0.000 description 2
238000000034 method Methods 0.000 description 2
230000004660 morphological change Effects 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
230000001790 virustatic effect Effects 0.000 description 2
GSLQFBVNOFBPRJ-YFKPBYRVSA-N (2s)-3-(6-aminopurin-9-yl)propane-1,2-diol Chemical compound NC1=NC=NC2=C1N=CN2C[C@H](O)CO GSLQFBVNOFBPRJ-YFKPBYRVSA-N 0.000 description 1
MZCFKCFREQWYEZ-XJSQPNRTSA-N 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound OC[C@H]1O[C@H](C[C@@H]1O)n1ccc(=O)[nH]c1=O.OC[C@H]1O[C@H](C[C@@H]1O)n1ccc(=O)[nH]c1=O MZCFKCFREQWYEZ-XJSQPNRTSA-N 0.000 description 1
VAQOTZQDXZDBJK-UHFFFAOYSA-N 2-(6-aminopurin-9-yl)ethanol Chemical compound NC1=NC=NC2=C1N=CN2CCO VAQOTZQDXZDBJK-UHFFFAOYSA-N 0.000 description 1
UHOFECKRSHSYNE-UHFFFAOYSA-N 3-(6-aminopurin-9-yl)-2-hydroxypropanoic acid Chemical class NC1=NC=NC2=C1N=CN2CC(O)C(O)=O UHOFECKRSHSYNE-UHFFFAOYSA-N 0.000 description 1
208000009663 Acute Necrotizing Pancreatitis Diseases 0.000 description 1
241000272525 Anas platyrhynchos Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
201000006082 Chickenpox Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
LIEMBEWXEZJEEZ-UHFFFAOYSA-N D-threo-Leutysin Natural products NC1=NC=NC2=C1N=CN2CC(O)C(O)C(O)=O LIEMBEWXEZJEEZ-UHFFFAOYSA-N 0.000 description 1
241000709661 Enterovirus Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
201000005505 Measles Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010029155 Nephropathy toxic Diseases 0.000 description 1
241000702244 Orthoreovirus Species 0.000 description 1
206010058096 Pancreatic necrosis Diseases 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
206010035148 Plague Diseases 0.000 description 1
206010035742 Pneumonitis Diseases 0.000 description 1
206010037742 Rabies Diseases 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
241000277331 Salmonidae Species 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
206010046306 Upper respiratory tract infection Diseases 0.000 description 1
206010046980 Varicella Diseases 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000002585 base Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000003559 chemosterilizing effect Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
LIEMBEWXEZJEEZ-UJURSFKZSA-N d-eritadenine Chemical compound NC1=NC=NC2=C1N=CN2C[C@H](O)[C@@H](O)C(O)=O LIEMBEWXEZJEEZ-UJURSFKZSA-N 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
231100000086 high toxicity Toxicity 0.000 description 1
238000002650 immunosuppressive therapy Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
201000006747 infectious mononucleosis Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
201000010666 keratoconjunctivitis Diseases 0.000 description 1
BRHPBVXVOVMTIQ-ZLELNMGESA-N l-leucine l-leucine Chemical compound CC(C)C[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O BRHPBVXVOVMTIQ-ZLELNMGESA-N 0.000 description 1
230000003902 lesion Effects 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
239000000203 mixture Substances 0.000 description 1
230000007694 nephrotoxicity Effects 0.000 description 1
231100000417 nephrotoxicity Toxicity 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
229940127073 nucleoside analogue Drugs 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
244000144977 poultry Species 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
208000020029 respiratory tract infectious disease Diseases 0.000 description 1
241000894007 species Species 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
208000003265 stomatitis Diseases 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
229940045145 uridine Drugs 0.000 description 1
208000005925 vesicular stomatitis Diseases 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Virology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Saccharide Compounds (AREA)

CS853018A 1985-04-25 1985-04-25 Remedy with antiviral effect CS263952B1 (en)

Priority Applications (17)

Application Number	Priority Date	Filing Date	Title
CS853018A CS263952B1 (en)	1985-04-25	1985-04-25	Remedy with antiviral effect
IL78553A IL78553A (en)	1985-04-25	1986-04-21	Therapeutic compositions of phosphonylmethoxyalkyl adenines
US06/854,087 US4724233A (en)	1985-04-25	1986-04-21	Therapeutical application of phosphonylmethoxyalkyl adenines
AU56468/86A AU586860B2 (en)	1985-04-25	1986-04-22	Therapeutical application of phosphonylmethoxyalkyl adenines
DK184186A DK167342B1 (da)	1985-04-25	1986-04-22	Terapeutisk praeparat til behandling af virussygdomme samt anvendelse af et 9-(fosfonylmetoxyalkyl)adeninderivat til fremstilling af praeparatet
PH33699A PH23112A (en)	1985-04-25	1986-04-24	Therapeutical application of phosphonylmethoxyalkyl adenines
NZ215939A NZ215939A (en)	1985-04-25	1986-04-24	Phosphonyl methoxyadenine antiviral compositions
EG241/86A EG18436A (en)	1985-04-25	1986-04-24	Therapeutical application of phosponylmethoxy-alkyl adenines
PT82457A PT82457B (pt)	1985-04-25	1986-04-24	Processo de preparacao de uma composicao farmaceutica com base em fosfonil-metoxi-alquil-adeninas com actividade antiviral
CA000507510A CA1272956A (en)	1985-04-25	1986-04-24	Therapeutical application of phosphonylmethoxy-alkyl adenines
GR861089A GR861089B (en)	1985-04-25	1986-04-24	Therapeutic application of phosponylmethoxy alkyl ademines
DE8686105776T DE3684363D1 (de)	1985-04-25	1986-04-25	Phosphonylmethoxyalkyl-adeninen zur behandlung von viruskrankheiten.
ZA863133A ZA863133B (en)	1985-04-25	1986-04-25	Therapeutical application of phosphonylmethoxyalkyl adenines
EP86105776A EP0205826B1 (de)	1985-04-25	1986-04-25	Phosphonylmethoxyalkyl-Adeninen zur Behandlung von Viruskrankheiten
JP61097811A JPH0692307B2 (ja)	1985-04-25	1986-04-25	アデニン誘導体の治療的適用
AT86105776T ATE73663T1 (de)	1985-04-25	1986-04-25	Phosphonylmethoxyalkyl-adeninen zur behandlung von viruskrankheiten.
HK217296A HK217296A (en)	1985-04-25	1996-12-19	Phosphonylmethoxyalkyl adenines for the treatment of virus diseases

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CS853018A CS263952B1 (en)	1985-04-25	1985-04-25	Remedy with antiviral effect

Publications (1)

Publication Number	Publication Date
CS263952B1 true CS263952B1 (en)	1989-05-12

Family

ID=5369042

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CS853018A CS263952B1 (en)	1985-04-25	1985-04-25	Remedy with antiviral effect

Country Status (17)

Country	Link
US (1)	US4724233A (de)
EP (1)	EP0205826B1 (de)
JP (1)	JPH0692307B2 (de)
AT (1)	ATE73663T1 (de)
AU (1)	AU586860B2 (de)
CA (1)	CA1272956A (de)
CS (1)	CS263952B1 (de)
DE (1)	DE3684363D1 (de)
DK (1)	DK167342B1 (de)
EG (1)	EG18436A (de)
GR (1)	GR861089B (de)
HK (1)	HK217296A (de)
IL (1)	IL78553A (de)
NZ (1)	NZ215939A (de)
PH (1)	PH23112A (de)
PT (1)	PT82457B (de)
ZA (1)	ZA863133B (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5047533A (en) *	1983-05-24	1991-09-10	Sri International	Acyclic purine phosphonate nucleotide analogs
CS264222B1 (en) *	1986-07-18	1989-06-13	Holy Antonin	N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5650510A (en) *	1986-11-18	1997-07-22	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
NZ222553A (en) *	1986-11-18	1991-07-26	Bristol Myers Co	Phosphonomethoxyalkylene purine and pyrimidine derivatives and pharmaceutical compositions
US5284837A (en) *	1988-05-06	1994-02-08	Medivir Ab	Derivatives of purine, process for their preparation and a pharmaceutical preparation
EP0353955A3 (de) *	1988-08-02	1991-08-14	Beecham Group Plc	Chemische Verbindungen
US5688778A (en) *	1989-05-15	1997-11-18	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	Nucleoside analogs
US5302585A (en) *	1990-04-20	1994-04-12	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
DE69129650T2 (de) *	1990-09-14	1999-03-25	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic, Prag/Praha	Wirkstoffvorläufer von Phosphonaten
JP3497505B2 (ja) *	1991-10-11	2004-02-16	インスティテュートオブオルガニックケミストリーアンドバイオケミストリーオブザアカデミーオブサイエンシズオブザチェコパブリック	抗ウイルス性非環式ホスホノメトキシアルキル置換アルケニル及びアルキニルプリン及びピリミジン誘導体
US6057305A (en) *	1992-08-05	2000-05-02	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	Antiretroviral enantiomeric nucleotide analogs
US5514798A (en) *	1993-06-02	1996-05-07	Gilead Sciences, Inc.	Method and cyclic carbonates for nucleotide analogues
KR100386685B1 (ko) *	1993-09-17	2003-12-31	길리애드 사이언시즈, 인코포레이티드	뉴클레오타이드동족체류
US5798340A (en)	1993-09-17	1998-08-25	Gilead Sciences, Inc.	Nucleotide analogs
US5468752A (en) *	1994-04-04	1995-11-21	Freeman; William R.	Treatment of conditions of abnormally increased intraocular pressure by administration of HPMPC and related phosphonylmethoxyalkylcytosines
EP0754046A1 (de) *	1994-04-04	1997-01-22	FREEMAN, William R.	Verwendung der phosphonylmethoxyalkyl-nukleoside zur behandlung des erhöhten innenaugendrucks
US5977061A (en) *	1995-04-21	1999-11-02	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	N6 - substituted nucleotide analagues and their use
US6093816A (en)	1996-06-27	2000-07-25	Isis Pharmaceuticals, Inc.	Cationic lipids
TWI230618B (en) *	1998-12-15	2005-04-11	Gilead Sciences Inc	Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
US6635278B1 (en)	1998-12-15	2003-10-21	Gilead Sciences, Inc.	Pharmaceutical formulations
US7205404B1 (en) *	1999-03-05	2007-04-17	Metabasis Therapeutics, Inc.	Phosphorus-containing prodrugs
US20030187261A1 (en) *	2000-01-07	2003-10-02	Libor Havlicek	Purine derivatives, process for their preparation and use thereof
OA12393A (en)	2000-07-21	2006-04-18	Gilead Sciences Inc	Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same.
CZ297267B6 (cs) *	2001-06-29	2006-10-11	Ústav organické chemie a biochemie AV CR	Deriváty pyrimidinu nesoucí fosfonátovou skupinu,zpusob jejich prípravy, jejich pouzití pro lécbu a farmaceutické prípravky tyto látky obsahující
US7214668B2 (en) *	2002-05-13	2007-05-08	Metabasis Therapeutics, Inc.	Phosphonic acid based prodrugs of PMEA and its analogues
AU2003235501A1 (en) *	2002-05-13	2003-11-11	Metabasis Therapeutics, Inc.	PMEA and PMPA cyclic producing synthesis
RU2225223C1 (ru) *	2002-06-14	2004-03-10	Закрытое акционерное общество Фирма "ВИТАФАРМА"	Лиофилизированная антигерпетическая вакцина
US7417036B2 (en) *	2002-11-12	2008-08-26	Tianjin Kinsly Pharmaceutical Co. Ltd.	Crystal form of adefovir dipivoxil and its preparation
SI1583542T1 (sl) *	2003-01-14	2008-12-31	Gilead Sciences Inc	Sestavki in postopki za kombinacijsko antivirusnoterapijo
EP1644389B1 (de)	2003-06-16	2011-01-19	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	Pyrimidinverbindungen mit phosphonatgruppen als antivirale nucleotidanaloga
CN1964967B (zh) *	2004-06-08	2014-04-16	症变治疗公司	路易斯酸介导的环状酯的合成
CN100338080C (zh) *	2004-06-16	2007-09-19	山东中科泰斗化学有限公司	9－[2－(膦羧基甲氧基)乙基]腺嘌呤双环醇酯及其制备方法
PL216369B1 (pl)	2004-07-27	2014-03-31	Gilead Sciences	Pochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV
EP1831235B1 (de)	2004-12-16	2013-02-20	The Regents of The University of California	Arzneimittel für die lungen
WO2006130217A2 (en) *	2005-04-01	2006-12-07	The Regents Of The University Of California	Substituted phosphate esters of nucleoside phosphonates
TWI471145B (zh)	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
TWI375560B (en)	2005-06-13	2012-11-01	Gilead Sciences Inc	Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
FR2908133B1 (fr) *	2006-11-08	2012-12-14	Centre Nat Rech Scient	Nouveaux analogues de nucleotides comme molecules precurseurs d'antiviraux
USRE45004E1 (en)	2007-06-18	2014-07-08	Sunshine Lake Pharma Co., Ltd.	Bromo-phenyl substituted thiazolyl dihydropyrimidines
TWI444384B (zh)	2008-02-20	2014-07-11	Gilead Sciences Inc	核苷酸類似物及其在治療惡性腫瘤上的用途
US7935817B2 (en) *	2008-03-31	2011-05-03	Apotex Pharmachem Inc.	Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
WO2010077613A1 (en)	2008-12-09	2010-07-08	Gilead Sciences, Inc.	Modulators of toll-like receptors
EP2411392B1 (de)	2009-03-26	2014-02-26	Daewoong Pharmaceutical Co., Ltd.	Neue kristallformen von adefovirdipivoxil und verfahren zu deren herstellung
US20110223131A1 (en)	2010-02-24	2011-09-15	Gilead Sciences, Inc.	Antiviral compounds
BR112013014485B1 (pt)	2010-12-10	2021-03-30	Sigmapharm Laboratories, Llc	Composições farmacêuticas compreendendo pró-fármacos análogos de nucleotídeos de fosfonato ativos por via oral e sistema de embalagem de recipiente/fechamento contendo as ditas composições
CN107056838A (zh)	2013-03-15	2017-08-18	加利福尼亚大学董事会	无环核苷膦酸二酯
WO2015038421A1 (en)	2013-09-10	2015-03-19	Dow Corning Corporation	Wear-resistant silicon eutectic alloy components and methods of making the same
AU2015217221A1 (en)	2014-02-13	2016-08-11	Ligand Pharmaceuticals, Inc.	Prodrug compounds and their uses
WO2015195538A1 (en)	2014-06-17	2015-12-23	Dow Corning Corporation	Decorative shape-cast articles made from silicon eutectic alloys, and methods for producing the same
WO2016001907A1 (en)	2014-07-02	2016-01-07	Prendergast Patrick T	Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
JP2017520545A (ja)	2014-07-02	2017-07-27	リガンド・ファーマシューティカルズ・インコーポレイテッド	プロドラッグ化合物およびそれらの使用
EP4140485A1 (de)	2014-07-11	2023-03-01	Gilead Sciences, Inc.	Modulatoren von toll-like-rezeptoren zur behandlung von hiv
SG11201701957XA (en)	2014-09-15	2017-04-27	Univ California	Nucleotide analogs
WO2017048956A1 (en)	2015-09-15	2017-03-23	The Regents Of The University Of California	Nucleotide analogs
HK1257270A1 (zh)	2015-09-15	2019-10-18	Gilead Sciences, Inc.	用於治療hiv的toll樣受體(tlr)調節劑
EP3372227A1 (de)	2017-03-06	2018-09-12	MH10 Spolka z ograniczona odpowiedzialnoscia	Tablettenformulierung von adefovir dipivoxil
CA3087932A1 (en)	2018-01-09	2019-07-18	Ligand Pharmaceuticals, Inc.	Acetal compounds and therapeutic uses thereof
KR20250052378A (ko)	2022-07-21	2025-04-18	안티바 바이오사이언시즈, 인크.	Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1523865A (en) *	1974-09-02	1978-09-06	Wellcome Found	Purine compunds and salts thereof
JPS52105195A (en) *	1976-03-01	1977-09-03	Wellcome Found	Substituted purine
US4230708A (en) *	1977-10-20	1980-10-28	Stichting Rega V.Z.W.	Therapeutic application of (S) -or (RS)-9-(2, 3-dihydroxypropyl) adenine for use as antiviral agents
CS233665B1 (en) *	1983-01-06	1985-03-14	Antonin Holy	Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene
CS238038B1 (en) *	1983-10-07	1985-11-13	Antonin Holy	Medical drug with antivirus effect

1985
- 1985-04-25 CS CS853018A patent/CS263952B1/cs not_active IP Right Cessation
1986
- 1986-04-21 IL IL78553A patent/IL78553A/xx not_active IP Right Cessation
- 1986-04-21 US US06/854,087 patent/US4724233A/en not_active Expired - Lifetime
- 1986-04-22 AU AU56468/86A patent/AU586860B2/en not_active Ceased
- 1986-04-22 DK DK184186A patent/DK167342B1/da not_active IP Right Cessation
- 1986-04-24 EG EG241/86A patent/EG18436A/xx active
- 1986-04-24 PT PT82457A patent/PT82457B/pt unknown
- 1986-04-24 NZ NZ215939A patent/NZ215939A/xx unknown
- 1986-04-24 GR GR861089A patent/GR861089B/el unknown
- 1986-04-24 CA CA000507510A patent/CA1272956A/en not_active Expired - Lifetime
- 1986-04-24 PH PH33699A patent/PH23112A/en unknown
- 1986-04-25 JP JP61097811A patent/JPH0692307B2/ja not_active Expired - Lifetime
- 1986-04-25 DE DE8686105776T patent/DE3684363D1/de not_active Expired - Lifetime
- 1986-04-25 ZA ZA863133A patent/ZA863133B/xx unknown
- 1986-04-25 EP EP86105776A patent/EP0205826B1/de not_active Expired - Lifetime
- 1986-04-25 AT AT86105776T patent/ATE73663T1/de not_active IP Right Cessation
1996
- 1996-12-19 HK HK217296A patent/HK217296A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
DK167342B1 (da)	1993-10-18
HK217296A (en)	1996-12-27
IL78553A (en)	1989-09-28
ATE73663T1 (de)	1992-04-15
PT82457B (pt)	1988-03-03
US4724233A (en)	1988-02-09
CA1272956A (en)	1990-08-21
JPH0692307B2 (ja)	1994-11-16
GR861089B (en)	1986-08-26
PT82457A (en)	1986-05-01
EP0205826A2 (de)	1986-12-30
EP0205826B1 (de)	1992-03-18
AU5646886A (en)	1986-10-30
AU586860B2 (en)	1989-07-27
DK184186A (da)	1986-10-26
DK184186D0 (da)	1986-04-22
IL78553A0 (en)	1986-08-31
NZ215939A (en)	1988-09-29
PH23112A (en)	1989-04-19
JPS61275218A (ja)	1986-12-05
EP0205826A3 (en)	1989-05-10
DE3684363D1 (de)	1992-04-23
ZA863133B (en)	1987-02-25
EG18436A (en)	1993-02-28

Legal Events

Date	Code	Title	Description
2000-06-14	MK4A	Patent expired	Effective date: 20000425

Publication	Publication Date	Title
CS263952B1 (en)	1989-05-12	Remedy with antiviral effect
De Clercq	2001	Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections
De Clercq	1987	S-Adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents
Clercq et al.	1986	A novel selective broad-spectrum anti-DNA virus agent
US5321030A (en)	1994-06-14	Creatine analogs having antiviral activity
De Clercq et al.	1982	In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds
De Clercq et al.	1985	Selective in vitro and in vivo activities of 5-(2-haloalkyl) pyrimidine nucleoside analogs, particularly 5-(2-chloroethyl)-2'-deoxyuridine, against herpes simplex virus
CA2222154A1 (en)	1996-12-19	Acyclovir derivatives for topical use
Zakirova et al.	2012	Phosphoramidate derivatives of acyclovir: Synthesis and antiviral activity in HIV-1 and HSV-1 models in vitro
JP4545434B2 (ja)	2010-09-15	抗ウイルス活性を有する６−‘２−（ホスホノメトキシ）アルコキシピリミジン誘導体
De Clercq	1984	The antiviral spectrum of (E)-5-(2-bromovinyl)-2′-deoxyuridine
AU623341B2 (en)	1992-05-14	Antiviral therapy for hepatitis b
EP0294443B1 (de)	1992-07-29	Verwendung von nukleosiden zur herstellung eines medikamentes zur behandlung von krankheiten, die durch einen retrovirus oder den hepatitis-b-virus verursacht werden
JPH0618786B2 (ja)	1994-03-16	医薬組成物
Machida et al.	1979	In vitro antiherpesviral activity of 5-alkyl derivatives of 1-β-d-arabinofuranosyluracil
De Clercq et al.	1981	Effects of E-5-(2-bromovinyl)-2'-deoxyuridine and other selective anti-herpes compounds on the induction of retrovirus particles in mouse BALB/3T3 cells
CS238038B1 (en)	1985-11-13	Medical drug with antivirus effect
CA1328865C (en)	1994-04-26	Composition and method for treating hepatitis virus infections using 1-(2'-deoxy-2'-fluoro-beta-d-arabino- furanosyl)-5-ethyluracil
Krečmerová	2012	Nucleoside and nucleotide analogues for the treatment of herpesvirus infections: Current stage and new prospects in the field of acyclic nucleoside phosphonates
Ayisi et al.	1985	Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with trifluorothymidine, phosphonoformate and acycloguanosine against herpes simplex viruses
Brandi et al.	2009	A new homodimer of aciclovir as a prodrug with increased solubility and antiviral activity
Park et al.	1983	Efficacy of (E)-5-(2-bromovinyl)-2′-deoxyuridine in the treatment of experimental herpes simplex virus encephalitis in mice
Barnard et al.	1997	Acyclic phosphonomethylether nucleoside inhibitors of respiratory viruses
Holliday et al.	1991	Inhibition of herpes simplex virus types 1 and 2 replication in vitro by mercurithio analogs of deoxyuridine
Michaelis et al.	2002	In vitro antiviral activity of aphidicolin and its derivates